Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07568704 · ClinicalTrials.gov registry record
Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images
A clinical trial, sponsored by Intalight.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07568704: Recruiting study, sponsored by Intalight.
NCT07568704 is a clinical trial that is actively recruiting participants, run by Intalight. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07568704 is actively recruiting participants, sponsored by Intalight.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the image quality and clinical utility of the OCTA images from the VG200D OCT device (investigational device) compared against the FA and ICGA images from the UWF Optos California (CA) device. Image assessment will be conducted by three expert image graders and involve the assessment of the images based on both image quality and clinical utility. Evidence for substantial equivalence will be obtained through establishing similar image evaluation results across the devices based on image quality and clinical utility.
Primary Outcome
The outcome measure is the image grading of retinal images including OCTA and FA and or ICGA images as graded by experts
Interventions
- DEVICE Dream OCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2026-08-31 |
What NCT07568704 shows while recruiting
NCT07568704 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dream OCT is the first listed.
NCT07568704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07568704 about?
NCT07568704 is a clinical study titled "Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images". The goal of this study is to evaluate the image quality and clinical utility of the OCTA images from the VG200D OCT device (investigational device) compared against the FA and ICGA images from the UWF Optos California (CA) device. Image assessment will be conducted by three expert image graders and ...
What is the current status of trial NCT07568704?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-03-25. Estimated completion is 2026-08-31.
What interventions are being tested in trial NCT07568704?
The interventions under investigation include: Dream OCT (DEVICE).
Who is sponsoring clinical trial NCT07568704?
This trial is sponsored by Intalight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI